Comparative Pharmacology
Head-to-head clinical analysis: BESIVANCE versus POLYTRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BESIVANCE versus POLYTRIM.
BESIVANCE vs POLYTRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BESIVANCE is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and leading to bacterial cell death.
Polymyxin B sulfate binds to the lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria, disrupting membrane integrity and causing cell death. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA synthesis.
One drop instilled into the affected eye(s) three times daily for 7 days.
1 drop in the affected eye(s) every 4 hours for 7-10 days.
None Documented
None Documented
Terminal half-life of approximately 1.5-2 hours in adults; prolongation in renal impairment.
Terminal elimination half-life of polymyxin B is 4.5-6 hours; for trimethoprim it is 8-10 hours. In renal impairment, half-life of both components is prolonged.
Primarily excreted unchanged in urine (approximately 50-60%) and feces (approximately 20-30%); biliary excretion contributes to fecal elimination.
Renal excretion accounts for approximately 40% of the dose as unchanged polymyxin B and 60% as unchanged trimethoprim. Biliary/fecal elimination is minimal (<5% for each component).
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic